Telemedicine Medicines in India: List O, A, B, Prohibitions and Amendments
Evaluate drug-list updates, consultation mode and follow-up eligibility before remote prescribing; handle refill requests without relying on a static prohibited list.
Controlled-medicine safeguards start with the exact medicine, formulation and activity. Schedule X under the Drugs Rules and controls under the NDPS framework are not interchangeable labels. Verify the current classification, clinical appropriateness and permissions for prescribing, possession or supply separately; an ordinary prescription workflow cannot establish all three.
Indian clinic owners, prescribing doctors and authorised pharmacy or stock staff reviewing controlled medicines, opioids and medicines with misuse potential.
The words opioid, psychotropic, sedative and Schedule X describe different things. Some are clinical or pharmacological terms; others refer to legal classifications. A clinic should not use one broad category as a substitute for checking the product actually being considered.
Start with the generic ingredient, strength, dosage form and any relevant combination or exemption. Confirm the authoritative schedule or notification and its date. A brand name alone is a poor basis for classification because similar names, formulations and product changes can create confusion.
The CDSCO Drugs Rules compilation includes Schedule X and licence conditions under Rule 65. The NDPS framework has separate controls, including provisions for essential narcotic drugs and recognised medical institutions. Identify the applicable provisions instead of assuming one authorisation covers every activity.
Record uncertainty explicitly. If a medicine’s current classification or the clinic’s authority is unresolved, route the question to the appropriate clinical, pharmacy or regulatory reviewer before taking the affected action. Do not make reception responsible for resolving an unfamiliar legal category during a busy session.
Source: CDSCO: Drugs Rules, 1945, compilation dated 9 September 2024
A doctor may encounter a patient already using a controlled medicine without the clinic possessing that medicine. Conversely, a clinic may hold stock for a defined service with specific responsibilities. The record, authorisation and operational questions differ between reviewing treatment, issuing an order, purchasing, storing, administering and dispensing.
Ask which legal entity and premises are involved. An authorisation held by a hospital, another branch or an associated pharmacy should not be assumed to cover stock in a consultation room elsewhere. Confirm the scope, conditions, responsible persons and validity of the actual permission.
Rule 65 includes specific Schedule X prescription and retention conditions for the relevant licence holder, including duplicate prescriptions and retaining a copy for two years. Do not generalise that provision into a universal two-year retention rule for every clinic record or every medicine with misuse potential.
Build the operating process only after the authority question is answered. Buying a lockable cupboard, adding an EMR flag or obtaining a patient signature cannot create permission to possess or supply a product. Those may be controls within an authorised process; they are not substitutes for it.
Source: CDSCO: Drugs Rules, 1945, compilation dated 9 September 2024
The following map is an original governance tool. It intentionally avoids listing medicines as permanently permitted or prohibited because classifications, formulations and notifications require current verification. Use a qualified reviewer to complete the entries relevant to the clinic.
Maintain the supporting evidence where authorised staff can retrieve it. A tick saying “approved” is weak if nobody can identify the approval, its scope or the person responsible for interpreting it.
On a narrow screen, scroll the table horizontally to read all columns.
| Decision | Evidence to obtain | Common mistaken shortcut |
|---|---|---|
| Product classification | Exact product and current authoritative classification | All medicines in a clinical class are treated identically |
| Clinical decision | Assessment, rationale and patient-specific review by the prescriber | A previous prescription is treated as automatic approval |
| Consultation mode | Applicable remote or in-person requirements and current medicine-list updates | Video consultation is assumed to override every restriction |
| Possession or supply authority | Relevant premises, licence or recognition and conditions | Another branch’s permission is copied without checking scope |
| Stock accountability | Authorised custody, movement evidence and discrepancy process | A spreadsheet balance is accepted without physical reconciliation |
A repeat request may arrive with an old prescription, an empty pack or a message from a relative. Establish what the patient actually uses, who prescribed it and what records are available. The clinician must assess the current situation rather than treating possession of an old document as a standing authorisation.
Record the reason for the decision and relevant uncertainty. If different prescribers or sources are involved, make that visible without making accusations. A discrepancy can arise from misunderstanding, changed instructions or incomplete records; it should prompt appropriate review, not a stigmatising label.
Do not impose an abrupt treatment change through an administrative rule. When supply or authority is uncertain, arrange timely clinical assessment and an appropriate continuity or referral plan. Staff should explain the next step respectfully and avoid promising a medicine before the prescriber has reviewed the situation.
Document the plan for monitoring and reassessment that the clinician actually selects. A generic “review regularly” checkbox does little to establish who will act on a concern or how a patient can obtain help. This article deliberately gives no dose, taper, substitution or withdrawal-management regimen.
Where the clinic is authorised to hold the medicine, define who can receive, access, administer, dispense and reconcile it. Match these responsibilities to the applicable rules and local authorisation. A shared cupboard key with no accountable handover is a weak foundation for any stock record.
Link each movement to its source evidence: receipt, authorised order, administration or supply record, return, loss investigation or approved disposal. Record units consistently. A balance expressed in packs while actual use is entered in tablets or millilitres can conceal a simple arithmetic error or a more serious discrepancy.
During handover, compare the recorded balance with the physical stock through the approved process. Investigate differences promptly and preserve the original entries. Do not add an unexplained “adjustment” merely to make the figures agree at month end.
Separate expired, damaged or otherwise unusable stock as required by the applicable procedure, and obtain the correct disposal or return route. Do not improvise destruction or transfer because a cupboard needs clearing. The authorisation and evidence for the action matter as much as the final stock number.
A dated legal compilation is a starting point, not proof that every subsequent change has been incorporated. Check the regulator’s notification index and the actual instrument for changes affecting the exact product or activity. Record the effective requirement and who reviewed it.
The CDSCO notification index includes both drafts and final instruments. For example, a proposed requirement should not be described as already binding merely because it appears on an official website. Read the legal status and commencement language before changing policy or publishing a claim.
Telemedicine needs an additional current-list check. The April 2020 amendment added named medicines to List A, illustrating why class-wide statements can be inaccurate. A narrow amendment should not be extended to other medicines by analogy, and it does not settle possession or supply permissions.
Have a named owner review material changes and update the clinic’s product-specific evidence map. Avoid making a live regulatory feed automatically enable medicine ordering without human interpretation. A change in a catalogue should not silently alter a clinical or legal permission.
Ask software vendors to show how product classifications are sourced and updated, whether formulation differences are represented and who can override a restriction. A label saying “NDPS compliant” is not enough to establish that the clinic’s actual activity is covered.
Use fictional cases: an old repeat request, an uncertain classification, a restricted account, a stock discrepancy and a remote consultation requiring further review. Observe whether the system preserves the question and routes it to an authorised person instead of forcing a misleading yes-or-no answer.
Inspect the exported record and audit history. The clinician’s rationale, order version and responsible staff should remain intelligible outside the application. Stock reconciliation should be traceable to movements rather than only a final balance.
Before enabling a workflow, list the gaps that software cannot decide: professional authority, premises permissions, current legal interpretation and patient-specific clinical judgment. Allocate those responsibilities explicitly. The software should support the authorised process that the clinic has established.
A fictional multi-location practice plans to move a medicine cupboard from one premises to another. The team initially treats the move as an inventory transfer. A product-and-activity review reveals that the relevant authority and custody arrangements need checking for the receiving premises. The clinic pauses the affected transfer, obtains competent guidance and documents the resulting authorised process. This example does not decide the permissions for any particular medicine; it shows why a stock transaction cannot answer a premises-authority question.
Use these prompts in your clinic’s own notes. Record the result, responsible person and next action for each item.
No. They belong to different regulatory frameworks and should be checked separately for the exact product and activity. Avoid assuming that a clinical term such as opioid or psychiatric medicine determines all applicable legal controls.
No. A clinical category is too broad for that conclusion. Verify the named ingredient, formulation, current schedules and relevant notifications. Telemedicine lists also have specific amendments, so a static class-wide rule can misstate the position.
Do not infer that. Possession, administration and supply can raise separate premises, licensing, recognition and record requirements. Obtain competent confirmation for the actual activity before using software settings or a cupboard arrangement as the operating process.
No. The cited Rule 65 provision has a specific licence-holder and prescription context. Other records, products, authorisations or proceedings may have different requirements. Build a scoped retention schedule instead of extending one number to the whole clinic.
Route it promptly to the responsible clinician and appropriate regulatory or pharmacy reviewer. Do not promise supply, make an unsupported classification or impose an abrupt treatment change. The patient may need a timely assessment and a safe continuity or referral plan.
Updated on . Governance guidance, not a medicine list, prescribing protocol or legal authorisation. Current product-specific law, competent-authority advice and clinical assessment are required before action. No independent clinical or legal review is claimed.
Includes Schedule X and Rule 65 licence conditions. A dated compilation must be checked against later final notifications and the exact formulation and activity.
Separate narcotic and psychotropic controls include provisions for essential narcotic drugs and recognised medical institutions. Verify current amendments and competent-authority requirements for the proposed activity.
Use the notification’s legal status and commencement, not its listing date alone. A draft proposal is not a final requirement.
Adds phenobarbitone, clobazam and clonazepam to List A for first and follow-up consultations. A specific amendment does not establish permission for every medicine in the same class.
Evaluate drug-list updates, consultation mode and follow-up eligibility before remote prescribing; handle refill requests without relying on a static prohibited list.
Check the issuing doctor, registration details and verified qualifications across clinic prescriptions, PDFs and reprints, including locums and multiple branches.
Audit drug search, lab directories and referral suggestions for paid influence; ask vendors for ranking explanations, change controls and reproducible evidence.
Use fictional controlled-medicine cases to ask Bractis about classification sources, authorised roles, order history and stock discrepancies. Confirm legal and clinical scope independently of any demonstrated software control.
Request a clinic demo